Mixed Methods Findings from a Stepped Wedge Hybrid Implementation Trial of ATTAIN NAV: A Mental Health Family Navigation Intervention for Autistic Youth.

J Autism Dev DisordMay 8, 2025 (epub)
Clinical ResearchPsychiatryPediatricsOpen access

Nicole A Stadnick, Kassandra Martinez, Felice Navarro et al.

✦ AI-curated · Sources linked

In 30 seconds

This mixed-methods, stepped-wedge hybrid implementation trial evaluated ATTAIN NAV, a family-navigation intervention intended to improve mental health service access and engagement for school-age autistic youth. The study enrolled 56 caregiver-child dyads through primary care providers at six California clinics, which were randomized to technology-enhanced or standard navigation. Across both conditions, child challenging behavior and parent activation improved; these gains were more pronounced with standard navigation. At post-intervention, standard-navigation families also reported greater satisfaction, shorter time to a first mental health appointment, and stronger navigator engagement.

Key findings

  • Child challenging behavior and parent activation improved across both navigation conditions, with more pronounced improvements in the standard condition.
  • Standard-navigation families reported higher navigation satisfaction and engagement with their navigator at post-intervention.
  • Families receiving standard navigation reported a shorter time to attend their first mental health appointment.

Why it matters

Autistic youth with mental health needs may face barriers to accessing and engaging with services. These findings suggest that family navigation can support clinical and service-related outcomes, while also indicating that technology enhancement did not correspond to stronger reported outcomes than standard navigation in this trial. The mixed-methods approach adds implementation perspectives alongside caregiver-reported outcomes.

What to keep in mind

The study included 56 caregiver-child dyads from six clinics in California, limiting the breadth of settings and populations represented. Outcomes were assessed at baseline and post-intervention, so longer-term effects are not established.

Source

Published in J Autism Dev Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.